Sonnet Biotherapeutics Holdings Stock Probability of Future Stock Price Finishing Under 6.97
| SONN Stock | USD 1.44 0.12 7.69% |
Sonnet |
Sonnet Biotherapeutics Target Price Odds to finish below 6.97
The tendency of Sonnet Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay under $ 6.97 after 90 days |
| 1.44 | 90 days | 6.97 | over 95.88 |
Based on a normal probability distribution, the odds of Sonnet Biotherapeutics to stay under $ 6.97 after 90 days from now is over 95.88 (This Sonnet Biotherapeutics Holdings probability density function shows the probability of Sonnet Stock to fall within a particular range of prices over 90 days) . Probability of Sonnet Biotherapeutics price to stay between its current price of $ 1.44 and $ 6.97 at the end of the 90-day period is about 88.9 .
Given the investment horizon of 90 days Sonnet Biotherapeutics Holdings has a beta of -0.0654. This usually implies as returns on the benchmark increase, returns on holding Sonnet Biotherapeutics are expected to decrease at a much lower rate. During a bear market, however, Sonnet Biotherapeutics Holdings is likely to outperform the market. Additionally Sonnet Biotherapeutics Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Sonnet Biotherapeutics Price Density |
| Price |
Predictive Modules for Sonnet Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sonnet Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sonnet Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Sonnet Biotherapeutics is not an exception. The market had few large corrections towards the Sonnet Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sonnet Biotherapeutics Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sonnet Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.31 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 1.72 | |
Ir | Information ratio | -0.32 |
Sonnet Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sonnet Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sonnet Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Sonnet Biotherapeutics generated a negative expected return over the last 90 days | |
| Sonnet Biotherapeutics has high historical volatility and very poor performance | |
| Sonnet Biotherapeutics may become a speculative penny stock | |
| Sonnet Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 18.63 K. Net Loss for the year was (7.44 M) with loss before overhead, payroll, taxes, and interest of (21.09 M). | |
| Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Latest headline from gurufocus.com: Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment |
Sonnet Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Sonnet Stock often depends not only on the future outlook of the current and potential Sonnet Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Sonnet Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 655.2 K | |
| Cash And Short Term Investments | 149.5 K |
Sonnet Biotherapeutics Technical Analysis
Sonnet Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Sonnet Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Sonnet Biotherapeutics Holdings. In general, you should focus on analyzing Sonnet Stock price patterns and their correlations with different microeconomic environments and drivers.
Sonnet Biotherapeutics Predictive Forecast Models
Sonnet Biotherapeutics' time-series forecasting models is one of many Sonnet Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Sonnet Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Sonnet Biotherapeutics
Checking the ongoing alerts about Sonnet Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Sonnet Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Sonnet Biotherapeutics generated a negative expected return over the last 90 days | |
| Sonnet Biotherapeutics has high historical volatility and very poor performance | |
| Sonnet Biotherapeutics may become a speculative penny stock | |
| Sonnet Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 18.63 K. Net Loss for the year was (7.44 M) with loss before overhead, payroll, taxes, and interest of (21.09 M). | |
| Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Latest headline from gurufocus.com: Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment |
Check out Sonnet Biotherapeutics Backtesting, Sonnet Biotherapeutics Valuation, Sonnet Biotherapeutics Correlation, Sonnet Biotherapeutics Hype Analysis, Sonnet Biotherapeutics Volatility, Sonnet Biotherapeutics History as well as Sonnet Biotherapeutics Performance. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.35) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.